Amedeo Smart

Free Medical Literature Service


 

Amedeo

Breast Cancer

  Free Subscription

Articles published in
J Clin Oncol
    September 2017
  1. IGLAY K, Santorelli ML, Hirshfield KM, Williams JM, et al
    Impact of Preexisting Mental Illness on All-Cause and Breast Cancer-Specific Mortality in Elderly Patients With Breast Cancer.
    J Clin Oncol. 2017 Sep 21:JCO2017734947. doi: 10.1200/JCO.2017.73.4947.
    >> Share

    August 2017
  2. GOETZ MP, Suman VJ, Reid JM, Northfelt DW, et al
    First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.
    J Clin Oncol. 2017 Aug 30:JCO2017733246. doi: 10.1200/JCO.2017.73.3246.
    >> Share

  3. KUIJER A, Straver M, den Dekker B, van Bommel ACM, et al
    Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen Receptor-Positive Early Breast Cancer: Results of a Prospective Cohort Study.
    J Clin Oncol. 2017;35:2814-2819.
    >> Share

  4. CHIEN AJ, Rugo HS
    Tyrosine Kinase Inhibitors for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Is Personalizing Therapy Within Reach?
    J Clin Oncol. 2017 Aug 7:JCO2017735670. doi: 10.1200/JCO.2017.73.5670.
    >> Share

    July 2017
  5. SJOSTROM M, Lundstedt D, Hartman L, Holmberg E, et al
    Response to Radiotherapy After Breast-Conserving Surgery in Different Breast Cancer Subtypes in the Swedish Breast Cancer Group 91 Radiotherapy Randomized Clinical Trial.
    J Clin Oncol. 2017 Jul 31:JCO2017727263. doi: 10.1200/JCO.2017.72.7263.
    >> Share

  6. FREEDMAN RA, Keating NL, Pace LE, Lii J, et al
    Use of Surveillance Mammography Among Older Breast Cancer Survivors by Life Expectancy.
    J Clin Oncol. 2017 Jul 27:JCO2016721209. doi: 10.1200/JCO.2016.72.1209.
    >> Share

  7. REEDER-HAYES KE, Meyer AM, Hinton SP, Meng K, et al
    Comparative Toxicity and Effectiveness of Trastuzumab-Based Chemotherapy Regimens in Older Women With Early-Stage Breast Cancer.
    J Clin Oncol. 2017 Jul 20:JCO2016714345. doi: 10.1200/JCO.2016.71.4345.
    >> Share

  8. FOURNIER A, Mesrine S, Gelot A, Fagherazzi G, et al
    Use of Bisphosphonates and Risk of Breast Cancer in a French Cohort of Postmenopausal Women.
    J Clin Oncol. 2017 Jul 14:JCO2016714337. doi: 10.1200/JCO.2016.71.4337.
    >> Share

  9. WALLNER LP, Li Y, Furgal AKC, Friese CR, et al
    Patient Preferences for Primary Care Provider Roles in Breast Cancer Survivorship Care.
    J Clin Oncol. 2017 Jul 12:JCO2017731307. doi: 10.1200/JCO.2017.73.1307.
    >> Share

  10. KROP I, Ismaila N, Andre F, Bast RC, et al
    Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update.
    J Clin Oncol. 2017 Jul 10:JCO2017740472. doi: 10.1200/JCO.2017.74.0472.
    >> Share

  11. TEEPEN JC, van Leeuwen FE, Tissing WJ, van Dulmen-den Broeder E, et al
    Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy.
    J Clin Oncol. 2017;35:2288-2298.
    >> Share

  12. ENRIGHT KA, Taback N, Powis ML, Gonzalez A, et al
    Setting Quality Improvement Priorities for Women Receiving Systemic Therapy for Early-Stage Breast Cancer by Using Population-Level Administrative Data.
    J Clin Oncol. 2017 Jul 6:JCO2016707950. doi: 10.1200/JCO.2016.70.7950.
    >> Share

  13. HARBECK N, Gluz O, Christgen M, Kates RE, et al
    De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and The
    J Clin Oncol. 2017 Jul 6:JCO2016719815. doi: 10.1200/JCO.2016.71.9815.
    >> Share

    June 2017
  14. CURIGLIANO G, Criscitiello C
    Maximizing the Clinical Benefit of Anthracyclines in Addition to Taxanes in the Adjuvant Treatment of Early Breast Cancer.
    J Clin Oncol. 2017 Jun 29:JCO2017725960. doi: 10.1200/JCO.2017.72.5960.
    >> Share

  15. EJLERTSEN B, Tuxen MK, Jakobsen EH, Jensen MB, et al
    Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial.
    J Clin Oncol. 2017 Jun 29:JCO2017723494. doi: 10.1200/JCO.2017.72.3494.
    >> Share

  16. SMITH SG, Sestak I, Howell A, Forbes J, et al
    Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I).
    J Clin Oncol. 2017 Jun 29:JCO2016717439. doi: 10.1200/JCO.2016.71.7439.
    >> Share

  17. SAHA P, Regan MM, Pagani O, Francis PA, et al
    Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.
    J Clin Oncol. 2017 Jun 27:JCO2016720946. doi: 10.1200/JCO.2016.72.0946.
    >> Share

  18. CHLEBOWSKI RT, Aragaki AK, Anderson GL, Thomson CA, et al
    Low-Fat Dietary Pattern and Breast Cancer Mortality in the Women's Health Initiative Randomized Controlled Trial.
    J Clin Oncol. 2017 Jun 27:JCO2016720326. doi: 10.1200/JCO.2016.72.0326.
    >> Share

  19. POWLES TJ, Paterson AHG, Gralow JR
    Optimal Use of Adjuvant Bisphosphonates and Breast Cancer.
    J Clin Oncol. 2017 Jun 27:JCO2017736157. doi: 10.1200/JCO.2017.73.6157.
    >> Share

  20. DHESY-THIND S, Fletcher GG, Blanchette PS, Clemons MJ, et al
    Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline.
    J Clin Oncol. 2017;35:2062-2081.
    >> Share

  21. STOLLEY M, Sheean P, Gerber B, Arroyo C, et al
    Efficacy of a Weight Loss Intervention for African American Breast Cancer Survivors.
    J Clin Oncol. 2017 Jun 19:JCO2016719856. doi: 10.1200/JCO.2016.71.9856.
    >> Share

  22. GONCALVES R, Reinert T, Ellis MJ
    Avoidance of Negative Results in Adjuvant Endocrine Therapy Trials for Estrogen Receptor-Positive Breast Cancer.
    J Clin Oncol. 2017 Jun 5:JCO2017730424. doi: 10.1200/JCO.2017.73.0424.
    >> Share

  23. GRIGGS JJ, Wolff AC
    Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Breast Cancer: More Breakthroughs and an Embarrassment of Riches.
    J Clin Oncol. 2017 Jun 3:JCO2017739375. doi: 10.1200/JCO.2017.73.9375.
    >> Share

  24. SLEDGE GW JR, Toi M, Neven P, Sohn J, et al
    MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
    J Clin Oncol. 2017 Jun 3:JCO2017737585. doi: 10.1200/JCO.2017.73.7585.
    >> Share

  25. WANDER SA, Mayer EL, Burstein HJ
    Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer.
    J Clin Oncol. 2017 Jun 3:JCO2017739482. doi: 10.1200/JCO.2017.73.9482.
    >> Share

  26. BEALE DJ
    Conclusion Based on Insufficient Data in Study of Protein Intake Association With Breast Cancer Survival.
    J Clin Oncol. 2017;35:1857.
    >> Share

    May 2017
  27. VENTZ S, Alexander BM, Parmigiani G, Gelber RD, et al
    Designing Clinical Trials That Accept New Arms: An Example in Metastatic Breast Cancer.
    J Clin Oncol. 2017 May 22:JCO2016701169. doi: 10.1200/JCO.2016.70.1169.
    >> Share

  28. MERETOJA TJ, Andersen KG, Bruce J, Haasio L, et al
    Clinical Prediction Model and Tool for Assessing Risk of Persistent Pain After Breast Cancer Surgery.
    J Clin Oncol. 2017;35:1660-1667.
    >> Share

  29. MA F, Li Q, Chen S, Zhu W, et al
    Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
    J Clin Oncol. 2017 May 12:JCO2016696179. doi: 10.1200/JCO.2016.69.6179.
    >> Share

  30. IRWIN MR, Olmstead R, Carrillo C, Sadeghi N, et al
    Tai Chi Chih Compared With Cognitive Behavioral Therapy for the Treatment of Insomnia in Survivors of Breast Cancer: A Randomized, Partially Blinded, Noninferiority Trial.
    J Clin Oncol. 2017 May 10:JCO2016710285. doi: 10.1200/JCO.2016.71.0285.
    >> Share

  31. KVILLEMO P, Mittendorfer-Rutz E, Branstrom R, Nilsson K, et al
    Sickness Absence and Disability Pension After Breast Cancer Diagnosis: A 5-Year Nationwide Cohort Study.
    J Clin Oncol. 2017 May 1:JCO2015660613. doi: 10.1200/JCO.2015.66.0613.
    >> Share

    April 2017
  32. HANNA WM, Slodkowska E, Lu FI, Nafisi H, et al
    Comparative Analysis of Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer According to 2007 and 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations.
    J Clin Oncol. 2017 Apr 26:JCO2016705319. doi: 10.1200/JCO.2016.70.5319.
    >> Share

  33. URRUTICOECHEA A, Rizwanullah M, Im SA, Ruiz ACS, et al
    Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Th
    J Clin Oncol. 2017 Apr 24:JCO2016706267. doi: 10.1200/JCO.2016.70.6267.
    >> Share

  34. MALY RC, Liang LJ, Liu Y, Griggs JJ, et al
    Randomized Controlled Trial of Survivorship Care Plans Among Low-Income, Predominantly Latina Breast Cancer Survivors.
    J Clin Oncol. 2017 Apr 18:JCO2016689497. doi: 10.1200/JCO.2016.68.9497.
    >> Share

  35. AHN S, Port ER
    Genetic Testing in Patients With Newly Diagnosed Breast Cancer: Room for Improvement.
    J Clin Oncol. 2017 Apr 14:JCO2017728816. doi: 10.1200/JCO.2017.72.8816.
    >> Share

  36. KURIAN AW, Li Y, Hamilton AS, Ward KC, et al
    Gaps in Incorporating Germline Genetic Testing Into Treatment Decision-Making for Early-Stage Breast Cancer.
    J Clin Oncol. 2017 Apr 12:JCO2016716480. doi: 10.1200/JCO.2016.71.6480.
    >> Share

  37. BLUM JL, Flynn PJ, Yothers G, Asmar L, et al
    Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
    J Clin Oncol. 2017 Apr 11:JCO2016714147. doi: 10.1200/JCO.2016.71.4147.
    >> Share

  38. BORGQUIST S, Giobbie-Hurder A, Ahern TP, Garber JE, et al
    Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study.
    J Clin Oncol. 2017;35:1179-1188.
    >> Share

    March 2017
  39. TAYLOR C, Correa C, Duane FK, Aznar MC, et al
    Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials.
    J Clin Oncol. 2017 Mar 20:JCO2016720722. doi: 10.1200/JCO.2016.72.0722.
    >> Share

  40. BARDIA A, Mayer IA, Diamond JR, Moroose RL, et al
    Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
    J Clin Oncol. 2017 Mar 14:JCO2016708297. doi: 10.1200/JCO.2016.70.8297.
    >> Share

  41. SONNENBLICK A, Agbor-Tarh D, Bradbury I, Di Cosimo S, et al
    Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.
    J Clin Oncol. 2017 Mar 13:JCO2016697722. doi: 10.1200/JCO.2016.69.7722.
    >> Share

    February 2017
  42. HUMMEL SB, van Lankveld JJ, Oldenburg HS, Hahn DE, et al
    Efficacy of Internet-Based Cognitive Behavioral Therapy in Improving Sexual Functioning of Breast Cancer Survivors: Results of a Randomized Controlled Trial.
    J Clin Oncol. 2017 Feb 27:JCO2016696021. doi: 10.1200/JCO.2016.69.6021.
    >> Share

    January 2017
  43. SYMMANS WF, Wei C, Gould R, Yu X, et al
    Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
    J Clin Oncol. 2017 Jan 30:JCO2015631010. doi: 10.1200/JCO.2015.63.1010.
    >> Share

  44. LOIBL S, Denkert C
    How Much Information Do We Really Need After Neoadjuvant Therapy for Breast Cancer?
    J Clin Oncol. 2017 Jan 30:JCO2016713503. doi: 10.1200/JCO.2016.71.3503.
    >> Share

  45. SMITH I, Yardley D, Burris H, De Boer R, et al
    Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluat
    J Clin Oncol. 2017 Jan 23:JCO2016692871. doi: 10.1200/JCO.2016.69.2871.
    >> Share

  46. CHERAGHI Z, Ayubi E, Doosti-Irani A
    Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: Methodologic Issues to Avoid Misinterpretation in the Meta-Analysis.
    J Clin Oncol. 2017 Jan 23:JCO2016710715. doi: 10.1200/JCO.2016.71.0715.
    >> Share

  47. HOLMES MD, Wang J, Hankinson SE, Tamimi RM, et al
    Protein Intake and Breast Cancer Survival in the Nurses' Health Study.
    J Clin Oncol. 2017;35:325-333.
    >> Share

  48. SUPPLI NP, Johansen C, Kessing LV, Toender A, et al
    Survival After Early-Stage Breast Cancer of Women Previously Treated for Depression: A Nationwide Danish Cohort Study.
    J Clin Oncol. 2017;35:334-342.
    >> Share

  49. VAN DEN BOGAARD VA, Ta BD, van der Schaaf A, Bouma AB, et al
    Validation and Modification of a Prediction Model for Acute Cardiac Events in Patients With Breast Cancer Treated With Radiotherapy Based on Three-Dimensional Dose Distributions to Cardiac Substructures.
    J Clin Oncol. 2017 Jan 17:JCO2016698480. doi: 10.1200/JCO.2016.69.8480.
    >> Share

  50. RECHT A
    Radiation-Induced Heart Disease After Breast Cancer Treatment: How Big a Problem, and How Much Can-and Should-We Try to Reduce It?
    J Clin Oncol. 2017 Jan 17:JCO2016714113. doi: 10.1200/JCO.2016.71.4113.
    >> Share

  51. DEL MASTRO L
    Optimal Adjuvant Chemotherapy Regimens for Patients With Early-Stage Breast Cancer.
    J Clin Oncol. 2017 Jan 17:JCO2016682393. doi: 10.1200/JCO.2016.68.2393.
    >> Share

  52. PEREZ EA, Barrios C, Eiermann W, Toi M, et al
    Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.
    J Clin Oncol. 2017;35:141-148.
    >> Share

  53. MEGGETTO O, Maunsell E, Chlebowski R, Goss P, et al
    Factors Associated With Early Discontinuation of Study Treatment in the Mammary Prevention.3 Breast Cancer Chemoprevention Trial.
    J Clin Oncol. 2017 Jan 9:JCO2016688895.
    >> Share

  54. ELLIS MJ, Suman VJ, Hoog J, Goncalves R, et al
    Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
    J Clin Oncol. 2017 Jan 3:JCO2016694406.
    >> Share

  55. FARIAS AJ, Du XL
    Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer.
    J Clin Oncol. 2017;35:86-95.
    >> Share

    December 2016
  56. CUZICK J, Brentnall AR, Segal C, Byers H, et al
    Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials.
    J Clin Oncol. 2016 Dec 28:JCO2016698944.
    >> Share

  57. CHLEBOWSKI RT
    Improving Breast Cancer Risk Assessment Versus Implementing Breast Cancer Prevention.
    J Clin Oncol. 2016 Dec 28:JCO2016709386.
    >> Share

  58. JANELSINS MC, Heckler CE, Peppone LJ, Kamen C, et al
    Cognitive Complaints in Survivors of Breast Cancer After Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide, Multicenter, Prospective Longitudinal Study.
    J Clin Oncol. 2016 Dec 28:JCO2016685856.
    >> Share

  59. KIM HS, Umbricht CB, Illei PB, Cimino-Mathews A, et al
    Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer.
    J Clin Oncol. 2016;34:4390-4397.
    >> Share

  60. FREEDMAN RA, Foster JC, Seisler DK, Lafky JM, et al
    Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527.
    J Clin Oncol. 2016 Dec 19:JCO2016694182.
    >> Share

  61. JIRALERSPONG S, Goodwin PJ
    Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities.
    J Clin Oncol. 2016;34:4203-4216.
    >> Share

    November 2016
  62. ALFANO CM, Peng J, Andridge RR, Lindgren ME, et al
    Inflammatory Cytokines and Comorbidity Development in Breast Cancer Survivors Versus Noncancer Controls: Evidence for Accelerated Aging?
    J Clin Oncol. 2016 Nov 28:JCO2016671883.
    >> Share

  63. VISVANATHAN K, Fackler MS, Zhang Z, Lopez-Bujanda ZA, et al
    Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study.
    J Clin Oncol. 2016 Nov 21:JCO2015662080.
    >> Share

  64. WALLNER LP, Abrahamse P, Uppal JK, Friese CR, et al
    Involvement of Primary Care Physicians in the Decision Making and Care of Patients With Breast Cancer.
    J Clin Oncol. 2016;34:3969-3975.
    >> Share

  65. JHAVERI K
    MARIANNE: Impact on Current Treatment of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Implications for the Future.
    J Clin Oncol. 2016 Nov 14:JCO2016702712.
    >> Share

    October 2016
  66. ZARDAVAS D, Suter TM, Van Veldhuisen DJ, Steinseifer J, et al
    Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Stud
    J Clin Oncol. 2016 Oct 23:JCO2015657916. doi: 10.1200/JCO.2015.65.7916.
    >> Share

    August 2016
  67. PRESS MF, Sauter G, Buyse M, Fourmanoir H, et al
    HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials.
    J Clin Oncol. 2016 Aug 29. pii: JCO666693.
    >> Share

  68. COPUR MS, Ramaekers R, Gauchan D, Norvell M, et al
    Recent ASCO Guideline on the Use of Biomarkers for Adjuvant Systemic Therapy in Early-Stage Invasive Breast Cancer.
    J Clin Oncol. 2016 Aug 22. pii: JCO682385.
    >> Share

  69. SGROI DC, Brufsky A
    Biomarkers for Early-Stage Breast Cancer: Clinical Utility for Extended Adjuvant Treatment Decisions.
    J Clin Oncol. 2016 Aug 22. pii: JCO672949.
    >> Share

  70. BRADBURY AR, Patrick-Miller L, Schwartz LA, Egleston BL, et al
    Psychosocial Adjustment and Perceived Risk Among Adolescent Girls From Families With BRCA1/2 or Breast Cancer History.
    J Clin Oncol. 2016 Aug 22. pii: JCO663450.
    >> Share

  71. MAYER EL, Burstein HJ
    Chemotherapy for Triple-Negative Breast Cancer: Is More Better?
    J Clin Oncol. 2016 Aug 22. pii: JCO684068.
    >> Share

  72. HASEGAWA T, Uno H, Wei LJ
    How To Summarize the Safety Profile of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy?
    J Clin Oncol. 2016 Aug 9. pii: JCO672055.
    >> Share

  73. PARTRIDGE AH, Hughes ME, Warner ET, Ottesen RA, et al
    Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival.
    J Clin Oncol. 2016 Aug 1. pii: JCO658013.
    >> Share

    July 2016
  74. BAIK SH, Gallo LC, Wells KJ
    Patient Navigation in Breast Cancer Treatment and Survivorship: A Systematic Review.
    J Clin Oncol. 2016 Jul 25. pii: JCO675454.
    >> Share

  75. GUENANCIA C, Lefebvre A, Cardinale D, Yu AF, et al
    Obesity as a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis.
    J Clin Oncol. 2016 Jul 25. pii: JCO674846.
    >> Share

  76. STRULOV SHACHAR S, Hurria A, Muss HB
    Targeted Therapies in Older Adults With Breast Cancer: What Do We Know?
    J Clin Oncol. 2016 Jul 18. pii: JCO688242.
    >> Share

  77. LAURING J, Wolff AC
    Evolving Role of the Estrogen Receptor as a Predictive Biomarker: ESR1 Mutational Status and Endocrine Resistance in Breast Cancer.
    J Clin Oncol. 2016 Jul 5. pii: JCO684720.
    >> Share

    June 2016
  78. COLLEONI M, Gray KP, Gelber S, Lang I, et al
    Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance For Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.
    J Clin Oncol. 2016 Jun 20. pii: JCO656595.
    >> Share

  79. JOHANNSEN M, O'Connor M, O'Toole MS, Jensen AB, et al
    Efficacy of Mindfulness-Based Cognitive Therapy on Late Post-Treatment Pain in Women Treated for Primary Breast Cancer: A Randomized Controlled Trial.
    J Clin Oncol. 2016 Jun 20. pii: JCO650770.
    >> Share

  80. SCHMIDT MK, Hogervorst F, van Hien R, Cornelissen S, et al
    Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.
    J Clin Oncol. 2016 Jun 6. pii: JCO665844.
    >> Share

  81. FRIBBENS C, O'Leary B, Kilburn L, Hrebien S, et al
    Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
    J Clin Oncol. 2016 Jun 6. pii: JCO673061.
    >> Share

    May 2016
  82. LENGACHER CA, Reich RR, Paterson CL, Ramesar S, et al
    Examination of Broad Symptom Improvement Resulting From Mindfulness-Based Stress Reduction in Breast Cancer Survivors: A Randomized Controlled Trial.
    J Clin Oncol. 2016 May 31. pii: JCO657874.
    >> Share

  83. LIVI L, Meattini I, Kaidar-Person O, Poortmans PM, et al
    Elective Nodal Irradiation in Breast Cancer: Time for Trials on the Basis of Tumor Biology.
    J Clin Oncol. 2016 May 23. pii: JCO664276.
    >> Share

  84. HINDIE E, Groheux D
    Internal Mammary Node Irradiation in Breast Cancer: The Issue of Patient Selection.
    J Clin Oncol. 2016 May 23. pii: JCO674531.
    >> Share

  85. RUGO HS, Rumble RB, Macrae E, Barton DL, et al
    Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.
    J Clin Oncol. 2016 May 23. pii: JCO671487.
    >> Share

  86. KUERER HM
    Proceed With Caution: Concerns Related to Routine Internal Mammary Lymph Node Radiation for Node-Positive Breast Cancer.
    J Clin Oncol. 2016 May 23. pii: JCO668046.
    >> Share

  87. JONES LW, Habel LA, Weltzien E, Castillo A, et al
    Exercise and Risk of Cardiovascular Events in Women With Nonmetastatic Breast Cancer.
    J Clin Oncol. 2016 May 23. pii: JCO656603.
    >> Share

  88. WOLMARK N, Mamounas EP, Baehner FL, Butler SM, et al
    Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/
    J Clin Oncol. 2016 May 23. pii: JCO626630.
    >> Share

  89. EKHOLM M, Bendahl PO, Ferno M, Nordenskjold B, et al
    Two Years of Adjuvant Tamoxifen Provides a Survival Benefit Compared With No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer: Long-Term Follow-Up (> 25 years) of the Phase III SBII:2pre Trial.
    J Clin Oncol. 2016 May 9. pii: JCO656272.
    >> Share

  90. MCCARTHY AM, Bristol M, Domchek SM, Groeneveld PW, et al
    Health Care Segregation, Physician Recommendation, and Racial Disparities in BRCA1/2 Testing Among Women With Breast Cancer.
    J Clin Oncol. 2016 May 9. pii: JCO660019.
    >> Share

  91. ACCORDINO MK, Wright JD, Vasan S, Neugut AI, et al
    Use and Costs of Disease Monitoring in Women With Metastatic Breast Cancer.
    J Clin Oncol. 2016 May 9. pii: JCO666313.
    >> Share

  92. CHECK DK, Samuel CA, Rosenstein DL, Dusetzina SB, et al
    Investigation of Racial Disparities in Early Supportive Medication Use and End-of-Life Care Among Medicare Beneficiaries With Stage IV Breast Cancer.
    J Clin Oncol. 2016 May 9. pii: JCO648162.
    >> Share

  93. AXILBUND JE
    Panel Testing Is Not a Panacea.
    J Clin Oncol. 2016;34:1433-5.
    >> Share

    April 2016
  94. RAYSON D
    White Knuckling.
    J Clin Oncol. 2016;34:1419-20.
    >> Share

  95. HART V, Sprague BL, Lakoski SG, Hampton JM, et al
    Trends in Health-Related Quality of Life After a Diagnosis of Ductal Carcinoma In Situ.
    J Clin Oncol. 2016;34:1323-9.
    >> Share

  96. CARMONA R, Zakeri K, Green G, Hwang L, et al
    Improved Method to Stratify Elderly Patients With Cancer at Risk for Competing Events.
    J Clin Oncol. 2016;34:1270-7.
    >> Share

  97. SMITH GL
    Toward Minimizing Overtreatment and Undertreatment of Ductal Carcinoma In Situ in the United States.
    J Clin Oncol. 2016;34:1172-4.
    >> Share

    March 2016
  98. PARK JH, Anderson WF, Gail MH
    Reply to L.A. Newman.
    J Clin Oncol. 2016;34:1014-5.
    >> Share

  99. ELKIN EB, Hudis CA
    Reply to L.A. Newman.
    J Clin Oncol. 2016;34:1015.
    >> Share

  100. AHN S, Port ER
    Lymphedema Precautions: Time to Abandon Old Practices?
    J Clin Oncol. 2016;34:655-8.
    >> Share

    February 2016
  101. RUDDY KJ, Risendal BC, Garber JE, Partridge AH, et al
    Cancer Survivorship Care: An Opportunity to Revisit Cancer Genetics.
    J Clin Oncol. 2016;34:539-41.
    >> Share

    January 2016
  102. YOO W, Ansa BE, Coughlin SS, Whitehead MS, et al
    Determinants of adherence to physical activity guidelines among overweight and obese African American breast cancer survivors: Implications for intervention approach.
    J Clin Oncol. 2016;34.
    >> Share

  103. CLEMONS MJ, Mazzarello S, Vandermeer L, Jones L, et al
    Weight control strategies in breast cancer patients: A systematic review.
    J Clin Oncol. 2016;34.
    >> Share

  104. HARRIGAN M, Cartmel B, Playdon M, Zhou Y, et al
    Effect of weight history on ability to lose weight after a 6-month randomized controlled weight loss trial in overweight breast cancer survivors: The Lifestyle, Exercise and Nutrition (LEAN) study.
    J Clin Oncol. 2016;34.
    >> Share

  105. BARRY WT, Ruddy KJ, Greaney M, Rosenberg SM, et al
    Impact of Young and Strong on physical activity in young breast cancer survivors.
    J Clin Oncol. 2016;34.
    >> Share

  106. HADDAD N, Schnyer R, Neri E, Packer MM, et al
    Moderators of acupuncture effectiveness in breast cancer survivors: Randomized clinical trial (RCT).
    J Clin Oncol. 2016;34.
    >> Share

  107. CHAMPION V
    Examining the relationship between social cognitive processing and depressive symptoms in long-term breast cancer survivors and their partners.
    J Clin Oncol. 2016;34.
    >> Share

  108. LEE S, Bae SY, Lee JE, Kim SW, et al
    Importance of surgical role on anxiety of patients with breast cancer: Twelve-month follow-up prospective study.
    J Clin Oncol. 2016;34.
    >> Share

  109. SILVA HC, Mapp G, Terrell D
    Implementation of distress screening for breast cancer patients.
    J Clin Oncol. 2016;34.
    >> Share

  110. BERYL L, Gillespie K, Rendle K, May SG, et al
    "Hot Girls Pearls" and other coping strategies for women experiencing adverse effects from endocrine therapy in the treatment of breast cancer.
    J Clin Oncol. 2016;34.
    >> Share

  111. COHEE AA, Monahan P, Stump TE, Miller K, et al
    Quality of life difficulties in partners of young breast cancer survivors.
    J Clin Oncol. 2016;34.
    >> Share

  112. ANSA BE, Yoo W, Whitehead MS, Coughlin SS, et al
    Breast cancer recurrence risk-reduction beliefs and behaviors among African American breast cancer survivors.
    J Clin Oncol. 2016;34.
    >> Share

  113. ROCK CL, Sedjo RL, Toriola A, Liu J, et al
    Changes in biomarkers and DNA methylation in breast cancer survivors enrolled in the ENERGY weight loss trial: A pilot study.
    J Clin Oncol. 2016;34.
    >> Share

  114. LIN JJ, Franco R, Egorova N
    Breast cancer: Does where you get treated affect survival?
    J Clin Oncol. 2016;34.
    >> Share

  115. YEAHIA R, Korenstein D
    The evidence base in support of breast cancer surveillance guidelines: Flying without a net?
    J Clin Oncol. 2016;34.
    >> Share

  116. LEE J, Kim Z, Lee MH, Lee I, et al
    Development of second primary cancers in breast cancer survivors.
    J Clin Oncol. 2016;34.
    >> Share

  117. GONZALES FA, Shariff-Marco S, Dwyer LA, Nuru-Jeter A, et al
    Discrimination and quality of life among breast cancer survivors.
    J Clin Oncol. 2016;34.
    >> Share

  118. BALLARD A
    Exploring factors influencing sexual satisfaction among breast cancer survivors: The role of sexual communication.
    J Clin Oncol. 2016;34.
    >> Share

  119. DEMICHELE A, Schapira MM, Glanz K, Blauch A, et al
    Association of anxiety and depressive symptoms with differing needs among recent breast cancer (BC) survivors.
    J Clin Oncol. 2016;34.
    >> Share

  120. CHEN SP, Horng CF, Hsieh LL, Hsu KH, et al
    A randomized controlled study for the long term follow-up of breast cancer survivors: A primary care physician (PCP) coordinated care delivery model.
    J Clin Oncol. 2016;34.
    >> Share

  121. PACKER MM, George H, Koopman C, Innominato PF, et al
    Associations between morning-evening chronotype, fatigue, and QOL in breast cancer survivors.
    J Clin Oncol. 2016;34.
    >> Share

  122. MUSTAFA ALI MK, Moeller M, Rybicki LA
    Timing of the survivorship visit and symptom prevalence in breast cancer survivors.
    J Clin Oncol. 2016;34.
    >> Share

  123. DE RIDDER M, Lamote J, Fontaine C, Van Parijs H, et al
    Health-related quality of life in breast cancer patients prior to and 3 years following adjuvant radiotherapy: Comparison between conventional and short-course, image-guided radiotherapy.
    J Clin Oncol. 2016;34.
    >> Share

  124. PAUL E, Yang GJ, Phillips S, Bowles J, et al
    A new paradigm for patient-centered breast cancer care.
    J Clin Oncol. 2016;34.
    >> Share

  125. VICINI FA
    The increasing role of breast cancer lymphedema screening, diagnosis, and management as part of evidence-based breast cancer survivorship.
    J Clin Oncol. 2016;34.
    >> Share

  126. MERRIMAN J, Gentry A, Ahrendt GM, Brufsky A, et al
    Predictors of trajectories of cognitive change in women with breast cancer.
    J Clin Oncol. 2016;34.
    >> Share

  127. SATPUTE SR
    Systematic development of a a breast cancer survivorship program at a small independent oncology practice.
    J Clin Oncol. 2016;34.
    >> Share

  128. SINHA AK, Hsu L, Patangan M, Le-Petross HT, et al
    Association between tumor stage of first non-metastatic breast cancer and second contralateral breast cancer.
    J Clin Oncol. 2016;34.
    >> Share

  129. FONTAINE C, Vanhoeij M, Lamote J, De Greve J, et al
    The influence of multidisciplinary rehabilitation on physical well-being and quality of life of breast cancer survivors.
    J Clin Oncol. 2016;34.
    >> Share

  130. DEMICHELE A, Schapira MM, Glanz K, Blauch A, et al
    Patient-reported outcomes (PROs), unmet need, and psychosocial adaptation among recent breast cancer (BC) survivors.
    J Clin Oncol. 2016;34.
    >> Share

  131. ESSER M, Singh N, Rowe J, McCann M, et al
    Measuring knowledge gained for young breast cancer survivors and co-survivors.
    J Clin Oncol. 2016;34.
    >> Share

  132. GUGLIELMINO J, Labban JD, Rugo HS, Anders CK, et al
    Emotional/psychological characteristics of women diagnosed with breast cancer following treatment: Participation versus nonparticipation in survivorship programs.
    J Clin Oncol. 2016;34.
    >> Share

  133. KHOSLA P, Molnar J, Corona ME, Garcia SM, et al
    Improving patient participation in a breast cancer survivorship program at a safety net hospital.
    J Clin Oncol. 2016;34.
    >> Share

  134. CORRELL JA, Peterson LL
    Psychosocial well-being assessment in women with breast cancer.
    J Clin Oncol. 2016;34.
    >> Share

  135. GROEN WG, Oldenburg HS, Wouters MW, Aaronson NK, et al
    Evaluation of an interactive portal for breast cancer survivors: Use, satisfaction, and preliminary effects.
    J Clin Oncol. 2016;34.
    >> Share

  136. ROSENBERG SM, Gelber SI, Ruddy KJ, Morgan E, et al
    Post-traumatic stress disorder in young breast cancer survivors.
    J Clin Oncol. 2016;34.
    >> Share

  137. MCDOWELL K, Brown S, Serrano M, Lai LL, et al
    Evaluating a clinically and culturally informed survivorship care plan trial for African American breast cancer survivors (AABCS).
    J Clin Oncol. 2016;34.
    >> Share

  138. YEE S, Glass K, Foong S, Kennedy ED, et al
    Perspective of young breast cancer survivors (BCS) on fertility preservation (FP) referral.
    J Clin Oncol. 2016;34.
    >> Share

  139. LI D
    Patterns of health care-related multimorbidity among breast cancer survivors.
    J Clin Oncol. 2016;34.
    >> Share

  140. TANO J, Conde FA
    Impact of chemotherapy on health-related quality of life among ethnically diverse breast cancer survivors treated with breast-conserving therapy.
    J Clin Oncol. 2016;34.
    >> Share

  141. HOCKING WG, Wiegmann D, Yen TY, Gribble M, et al
    Evaluation of electronic care plan usage and usefulness among breast cancer survivors.
    J Clin Oncol. 2016;34.
    >> Share

  142. TSUCHIYA K, Nishijima C, Suzuki N, Tsugawa K, et al
    Our act on fertility preservation for young breast cancer patients in our single institute.
    J Clin Oncol. 2016;34.
    >> Share

  143. ABRAHAMSE P, Friese CR, Katz SJ, Hawley ST, et al
    Primary care provider engagement about breast cancer care during treatment: Results from the iCanCare Study.
    J Clin Oncol. 2016;34.
    >> Share

  144. PIACENTINE LB, Robinson KM, Ng AV, Waltke LJ, et al
    Underserved community-based walking program for breast cancer survivors.
    J Clin Oncol. 2016;34.
    >> Share

  145. ZHENG L, Graves KD, Hurtado-de-Mendoza A, Tadasse M, et al
    Opportunities for precision medicine: Factors associated with participation in genetic research among breast cancer survivors.
    J Clin Oncol. 2016;34.
    >> Share

  146. GROOME P, Turner D, Jorgensen M, Kendell C, et al
    Using Canadian administrative data to evaluate primary and oncology care of breast cancer patients post-treatment: Subset of the CanIMPACT Study.
    J Clin Oncol. 2016;34.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016